Drug Detailing and Doctors' Prescription Decisions: The Role of Information Content in the Face of Competitive Entry

We study the effects of information content in 59,814 pharmaceutical sales calls on doctors’ prescription decisions for statins, in the face of entry of competing brands and generics, using a hierarchical Bayesian distributed lag model. We conclude that adding information content to the prescription response model improves the in- and out-of-sample performance of the model. In the first six months following generic entry, it is more effective for incumbent brands to detail on drug contraindications and indications, compared to other periods, to positively differentiate from generics. In the first six months following branded entry, it is less effective for incumbent brands to detail on drug indications and costs, given increased competitive clutter. We also document substantial heterogeneity among doctors in their response to information content. Our model is helpful for analysts to more accurately assess the effectiveness of detailing. Our empirical results are also informative for drug manufacturers as they set or change their messaging policies in response to entry and help firms to tailor their message content at the doctor level.Data, as supplemental material, are available at https://doi.org/10.1287/mksc.2015.0971 .

[1]  M. Kyle,et al.  The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches , 2003 .

[2]  David R. Anderson,et al.  Multimodel Inference , 2004 .

[3]  Füsun F. Gönül,et al.  Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior , 2001 .

[4]  Evaluating statin drugs to treat: High Cholesterol and Heart Disease , 2010 .

[5]  Naveen Donthu,et al.  The Impact Of Content And Design Elements On Banner Advertising Click-Through Rates , 2003 .

[6]  P. Hewson.  Bayesian Data Analysis 3rd edn A. Gelman, J. B. Carlin, H. S. Stern, D. B. Dunson, A. Vehtari and D. B. Rubin, 2013 Boca Raton, Chapman and Hall–CRC 676 pp., £44.99 ISBN 1‐439‐84095‐4 , 2015 .

[7]  Sönke Albers,et al.  Personal Selling Elasticities: A Meta-Analysis , 2010 .

[8]  Jeremy Quirk,et al.  Rosuvastatin calcium , 2003, Nature Reviews Drug Discovery.

[9]  Sriram Venkataraman,et al.  The Relationship between DTCA, Drug Requests and Prescriptions: Uncovering Variation in Specialty and Space , 2012, Mark. Sci..

[10]  Andrew T. Ching,et al.  Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs after Patent Expiration , 2001 .

[11]  Pradeep Chintagunta,et al.  Assessing the Effect of Marketing Investments in a Business Marketing Context , 2011, Mark. Sci..

[12]  Prabhakant Sinha,et al.  Sales Force Effectiveness: A Framework for Researchers and Practitioners , 2008 .

[13]  E. Kappe.  Pharmaceutical Lifecycle Extension Strategies , 2014 .

[14]  E. Roughead,et al.  Self-Regulatory Codes of Conduct: Are They Effective in Controlling Pharmaceutical Representatives' Presentations to General Medical Practitioners? , 1998, International journal of health services : planning, administration, evaluation.

[15]  Venkatesh Shankar.  New Product Introduction and Incumbent Response Strategies: Their Interrelationship and the Role of Multimarket Contact , 1999 .

[16]  Natalie Mizik,et al.  Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions , 2004, Manag. Sci..

[17]  D. Kessler,et al.  Demand Effects of Recent Changes in Prescription Drug Promotion , 2003 .

[18]  H. Gatignon,et al.  Competitive Reactions to Market Entry: Explaining Interfirm Differences , 1989 .

[19]  J. M. Villas-Boas,et al.  Endogeneity in Brand Choice Models , 1999 .

[20]  Marc Fischer,et al.  Patient-or Physician-Oriented Marketing: What Drives Primary Demand for Prescription Drugs? , 2010 .

[21]  P. Greenland,et al.  Critical lessons from the ENHANCE trial. , 2008, JAMA.

[22]  Scott A. Sisson,et al.  Reversible Jump MCMC , 2011 .

[23]  D. Wittink,et al.  Building Models for Marketing Decisions , 2000 .

[24]  C. Sismeiro,et al.  Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules , 2008 .

[25]  Michael R. Ward,et al.  Generic Drug Industry Dynamics , 2002, Review of Economics and Statistics.

[26]  Inge Geyskens,et al.  What Makes Consumers Willing to Pay a Price Premium for National Brands over Private Labels? , 2010 .

[27]  Peter J. Danaher,et al.  The Effect of Competitive Advertising Interference on Sales for Packaged Goods , 2008 .

[28]  G. Guyatt,et al.  Assessing the quality of drug detailing. , 2002, Journal of clinical epidemiology.

[29]  S. Kälvemark Sporrong,et al.  Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin , 2012, The International journal of pharmacy practice.

[30]  Peter E. Rossi,et al.  Response Modeling with Nonrandom Marketing-Mix Variables , 2004 .

[31]  D. Rubin,et al.  Inference from Iterative Simulation Using Multiple Sequences , 1992 .

[32]  Sridhar Narayanan,et al.  Heterogeneous Learning and the Targeting of Marketing Communication for New Products , 2009, Mark. Sci..

[33]  Oliver Richard,et al.  Persistence in prescriptions of branded drugs , 2004 .

[34]  Fred M. Feinberg,et al.  The Shape of Advertising Response Functions Revisited: A Model of Dynamic Probabilistic Thresholds , 2004 .

[35]  R. Chandy,et al.  What to Say When: Advertising Appeals in Evolving Markets , 2001 .

[36]  Randall D. Beer,et al.  Information Processing and Dynamics in Minimally Cognitive Agents , 2015, Cogn. Sci..

[37]  Dominique M. Hanssens,et al.  Market Response Models: Econometric and Time Series Analysis , 1989 .

[38]  G. Urban,et al.  Information, marketing, and pricing in the U.S. antiulcer drug market. , 1995, The American economic review.

[39]  Puneet Manchanda,et al.  Quantifying the Benefits of Individual-Level Targeting in the Presence of Firm Strategic Behavior , 2009 .

[40]  Leonard M. Lodish,et al.  How T.V. Advertising Works: A Meta-Analysis of 389 Real World Split Cable T.V. Advertising Experiments , 1995 .

[41]  S. Hyman,et al.  Characteristics and Impact of Drug Detailing for Gabapentin , 2007, PLoS medicine.

[42]  Sendhil Mullainathan,et al.  What's Advertising Content Worth? Evidence from a Consumer Credit Marketing Field Experiment , 2009 .

[43]  John Geweke,et al.  Evaluating the accuracy of sampling-based approaches to the calculation of posterior moments , 1991 .

[44]  Generic Drug Industry Dynamics , 2002 .

[45]  Peter Meredith,et al.  Bioequivalence and other unresolved issues in generic drug substitution. , 2003, Clinical therapeutics.

[46]  Antonio G. Chessa,et al.  A Neurocognitive Model of Advertisement Content and Brand Name Recall , 2007 .

[47]  M. Ziegler,et al.  The accuracy of drug information from pharmaceutical sales representatives. , 1995, JAMA.

[48]  Venkatesh Shankar,et al.  Pioneers' Marketing Mix Reactions to Entry in Different Competitive Game Structures: Theoretical Analysis and Empirical Illustration , 1997 .

[49]  The effect of customer empowerment on adherence to expert advice , 2014 .

[50]  Dhaval M. Dave.  Effects of Pharmaceutical Promotion: A Review and Assessment , 2013 .

[51]  M. Kyle,et al.  The Long Shadow of Patent Expiration , 2003 .

[52]  Henry A Waxman,et al.  The lessons of Vioxx--drug safety and sales. , 2005, The New England journal of medicine.

[53]  Sumio Watanabe,et al.  Asymptotic Equivalence of Bayes Cross Validation and Widely Applicable Information Criterion in Singular Learning Theory , 2010, J. Mach. Learn. Res..

[54]  Pradeep K. Chintagunta,et al.  Temporal Differences in the Role of Marketing Communication in New Product Categories , 2005 .

[55]  Kissan Joseph,et al.  Sales force modeling: State of the field and research agenda , 2010 .

[56]  John K. Kruschke,et al.  An Evolutionary Analysis of Learned Attention , 2015, Cogn. Sci..

[57]  M Alan Brookhart,et al.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. , 2008, JAMA.

[58]  Stefan Stremersch,et al.  Marketing of the Life Sciences: A New Framework and Research Agenda for a Nascent Field , 2009 .

[59]  Jeffrey S. Rosenthal,et al.  Optimal Proposal Distributions and Adaptive MCMC , 2011 .

[60]  H. Heinz.  Promotion of Prescription Drugs and Its Impact on Physicians' Choice , 2016 .

[61]  Sriram Venkataraman,et al.  The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link? , 2007, Manag. Sci..